ZLAB — Zai Lab Limited

Zai Lab Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total revenues reached $116.1 million, a 14% year-over-year increase.
• VYVGART and VYVGART Hytrulo contributed $27.7 million, impacted by a $2.4 million price adjustment to align with NRDL guidelines.
• Adjusted loss from operations improved 42% year-over-year to $28 million; loss from operations was $48.8 million, a 28% improvement.
• Cash position at the end of the quarter was $817 million, providing flexibility for investments.
• Full-year revenue guidance updated to at least $460 million.

2. Strategic Updates and Business Highlights:

• Zai Lab's pipeline is advancing rapidly, with Zoci (ZL-1310) entering pivotal trials for extensive stage small cell lung cancer, aiming for global approval by 2027 or early 2028.
• Other promising assets include ZL-1503 (IL-13/IL-31 bispecific for atopic dermatitis), ZL-6201 (LRRC15 ADC), and ZL-1222 (PD-1 IL-12 immunocytokine).
• VYVGART continues to show strong launch performance, with 21,000 patients treated and a shift towards longer treatment durations.
• The company is focusing on building a global R&D organization and expanding its commercial presence in China.

3. Forward Guidance and Outlook:

• Anticipated growth drivers include VYVGART, ZEJULA, and new launches like KarXT, which is under regulatory review.
• The company expects continued growth in VYVGART driven by patient demand and treatment duration, with a goal of reaching an average of 3 treatment cycles per patient.
• Profitability is anticipated to shift beyond Q4 2025, with a focus on sustained revenue growth in China.

4. Bad News, Challenges, or Points of Concern:

• The pace of market development for VYVGART has been slower than expected, with challenges in achieving treatment duration similar to Western markets.
• ZEJULA's growth has been impacted by competitive dynamics and supply constraints, although a return to growth is expected as Lynparza goes generic.
• The company faces a complex and dynamic regulatory environment in China, which could affect future growth.
• Concerns regarding the approval pathway for Bema, given recent negative data from related trials.

5. Notable Q&A Insights:

• Management emphasized the importance of patient education and adherence to treatment protocols to enhance VYVGART's market penetration.
• There is optimism about the potential of Zoci in neuroendocrine tumors, with plans for a single-arm trial to assess efficacy.
• The company remains committed to balancing internal pipeline development with strategic external opportunities, focusing on oncology and autoimmune diseases.
• Management acknowledged the need to adjust expectations regarding the $2 billion revenue target by 2028, citing the evolving landscape and the performance of key products.

Overall, Zai Lab is navigating a complex market while advancing a promising pipeline, though it faces challenges in achieving its growth targets and managing competitive pressures.